Zhuang certainly didn't go.

$Brooklyn ImmunoTherapeutics (BTX.US)$ 14.75
Headquartered in Brooklyn, New York, USA, is a biopharmaceutical company focused on exploring the role of cytokine and gene editing/cell therapy in treating cancer patients, blood diseases, and monogene diseases. He has just hired Kevin A. D'Amour as the chief scientist with a salary of 410,000 US dollars a year, PhD at the University of California, age 48. Kevin A. D'Amour has previously been Chief Scientist at Viacyte, Inc., a private clinical stage company developing stem cell-based therapies for type 1 and insulin-dependent type 2 diabetes mellitus, most recently as the company's chief scientific officer. With over 100 U.S. and international patents, his significant experience in early to clinical success in cell and gene modified cell therapy makes him a great fit for Brooklyn, as we are working on what we believe will be pioneering work in multiple application areas, many of which are currently “There are no treatments available,” said Howard J. Federoff, MD, CEO and President of Brooklyn. “We look forward to moving our work forward under Kevin's leadership, and we welcome him to Brooklyn.” Brooklyn's exclusive access to Factor Bioscience and Novellus technologies for mRNa-based gene editing and cell reprogramming, combined with the new mRNA delivery system, provides a powerful technology platform and a myriad of compelling treatments. “I look forward to helping successfully apply these methods to clinical and ultimately patients,” added Dr. D'Amour. About Brooklyn Immunotherapy Brooklyn focuses on exploring the role of cytokin-based therapies in treating cancer patients, whether as monodrug or in combination with other anti-cancer therapies. The company also explores opportunities to advance the treatment of oncology, hematology and monogenic disease with highly innovative gene editing/cell therapy technologies, through newly licensed Factor Bioscience and Novellus Therapeutics.